The hypothesis of no difference in screening performance before and after implementation of Infcare Hepatitis was tested by McNemar’s test. Results: 76 patients were registered as active cirrhosis patients in the Infcare Hepatitis database at baseline and the study-cohort consisted of the 51 patients (37 men and 14 women; mean age of 53 years) still registered as being active at two-years follow-up. HCC screening by US had never been performed in 5 patients (10%) at baseline, and among the remaining 46 patients 14 (27%)

had not been screened for an extended period of 15 months and more. At follow-up, no patients had been left without previous screening, whereas 8 VEGFR inhibitor (16%) patients had not been screened within the last 15 months. Hence, the screening performance increased from 63% at baseline to 84% at follow-up (p=0.05). Conclusions: HCC screening performance improved after implementation of Infcare Hepatitis. Likely due to the relatively small size of the study-cohort, the difference did not reach statistically significance. It should be noticed that there were still cirrhotic patients at follow-up who had not been screened for HCC by US on annual basis in accordance to the existing guidelines. The concept of

using a system like Infcare Hepatitis with clinical decision-support and QA modules for the purpose of improving management of chronic Selleckchem Trichostatin A viral hepatitis patients seems promising. However there still remain other potential obstacles related to user application and system operation,

which needs to be further addressed before InfCare Hepatitis can reach a satisfactory outcome level aiming at higher quality of care. Disclosures: Peter Leutscher – Advisory Committees or Review Panels: Gilead, MSD; Consulting: Abbvie; Grant/Research Support: Roche The following people have nothing to disclose: Patricia Fruelund, Carsten S. Larsen, Mogens Erlandsen Background: We previously conducted studies of effect of patients distance on outcomes post liver transplantation (LTx)(AASLD 2012), using KM, the AIC criterion applied to Cox PH, AFT and Logistic Regression to establish tuclazepam a distance effect at 1 80 miles. We hypothesize a point in time when the effect of distance on post LT survival changes. This study aimed to examine outcomes of LT recipients based on distance from a transplant center and look for a change point while adjusting for hepatitis C (HCV) and hepatocellular carcinoma (HCC). Methods: A retrospective single center study of 821 LTx recipients between 1 996 and 2012 was conducted. A change point and a dichotomization point were inserted into the hazard function. The log-likelihood function was optimized using Nelder-Mead (NM) algorithm, a variable metric algorithm, and a simulated annealing algorithm. The goal was to simultaneously estimate the change point in the hazard function, the distance cutoff, the two relevant coefficients, as well as the coefficients for HCV and HCC.